Calcitonin

Drug class: Antineoplastic Agents

Usage of Calcitonin

Paget Disease of Bone

Treatment of Paget disease of bone. Consider treatment with calcitonin or a bisphosphonate (e.g., alendronate, etidronate, pamidronate, risedronate) in patients with biochemical markers suggestive of an increase in bone remodeling, those who are symptomatic, and those at risk for future complications from their disease (e.g., those with pagetic lesions in weight-bearing regions or adjacent to joints).

Hypercalcemia

Early treatment of hypercalcemic emergencies (with other appropriate agents) when a rapid decrease in serum calcium concentration is required.

Postmenopausal Osteoporosis

Treatment of postmenopausal osteoporosis in women >5 years postmenopause.

In addition to adequate intake of calcium/vitamin D and other lifestyle modifications (e.g., exercise, avoidance of excessive alcohol and tobacco use), experts recommend that pharmacologic therapy for osteoporosis be considered in postmenopausal women with high risk of fractures (generally those who have experienced a previous hip or vertebral fracture or who have low BMD); pharmacologic therapy also may be considered in postmenopausal women with low bone mass, although there is less evidence supporting overall fracture risk reduction in such patients.

Use of a drug with proven antifracture efficacy is recommended; experts generally recommend calcitonin as a last-line therapy when other drugs are not effective or tolerated.

Individualize choice of therapy based on potential benefits (with respect to fracture risk reduction) and adverse effects of therapy, patient preferences, comorbidities, and risk factors.

Glucocorticoid-induced Osteoporosis

Has been used in the treatment of glucocorticoid-induced osteoporosis† [off-label]; however, other therapies (e.g., oral bisphosphonates) are preferred.

Relate drugs

How to use Calcitonin

General

Paget Disease of Bone

  • Monitor by periodic determinations of serum alkaline phosphatase and urinary hydroxyproline excretion as well as evaluation of symptoms.
  • Investigate possibility of antibody formation in any patient who shows initial response but subsequently relapses.

    • Postmenopausal Osteoporosis

  • Monitor BMD.

    • Administration

    Administer by sub-Q or IM injection (Paget disease of bone, hypercalcemia, postmenopausal osteoporosis) or intranasally (postmenopausal osteoporosis).

    IM Administration

    IM injection preferred when injection volume >2 mL.

    Use multiple sites of injection when volume >2 mL.

    Sub-Q Administration

    Sub-Q injection preferred for patient self-administration.

    Intranasal Administration

    Administer once daily (as a single spray in 1 nostril) using metered-dose spray pump supplied by manufacturer. Alternate nostrils daily.

    Allow solution to reach room temperature before priming pump and administering first dose.

    Prime pump before first dose; do not prime before each dose.

    Miacalcin: To prime pump, hold bottle upright and depress the 2 white side arms of pump toward the bottle until full spray is produced.

    Fortical: To prime pump, hold bottle upright and depress the 2 white side arms of pump toward the bottle at least 5 times until full spray is produced.

    Administer dose by placing nozzle in nostril with head in upright position and firmly depressing pump toward bottle.

    Discard spray pump after 30 actuations, since the correct drug dose per actuation cannot be assured if used for additional doses.

    Dosage

    Activity of calcitonin salmon expressed in terms of International Units (units).

    Intranasal spray pumps deliver 0.09 mL of solution per actuation; each 0.09-mL spray delivers 200-unit dose.

    Adults

    Paget Disease of Bone Sub-Q or IM

    Initial dosage: 100 units (0.5 mL) daily.

    Maintenance: 50 units (0.25 mL) daily or every other day; higher dosage (100 units daily) appropriate in patients with serious deformity or neurologic involvement.

    Dosage >100 units daily usually does not produce an improved response in patients who relapse while receiving calcitonin.

    Hypercalcemia Sub-Q or IM

    Initially, 4 units/kg every 12 hours; may increase dosage after 1 or 2 days (if response not adequate) to 8 units/kg every 12 hours; may further increase dosage after 2 days (if response not adequate) to 8 units/kg every 6 hours.

    Postmenopausal Osteoporosis Sub-Q or IM

    Minimum effective dosage not established; 100 units every other day may be effective in preserving vertebral BMD.

    Intranasal

    200 units (1 spray) daily.

    Prescribing Limits

    Adults

    Hypercalcemia Sub-Q or IM

    Maximum 8 units/kg every 6 hours.

    Warnings

    Contraindications

  • Known hypersensitivity to calcitonin salmon.

    • Warnings/Precautions

    Sensitivity Reactions

    Serious allergic reactions (bronchospasm, swelling of tongue or throat, anaphylactic shock, at least 1 death due to anaphylaxis) reported in patients receiving Calcitonin injection. Differentiate hypersensitivity reactions from generalized flushing and hypotension.

    Allergic-type reactions also reported in patients receiving Calcitonin nasal spray.

    Appropriate agents for treatment of hypersensitivity reactions should be readily available.

    For patients with suspected sensitivity to calcitonin, consider skin testing prior to initiating therapy.

    General Precautions

    Hypocalcemic Tetany

    Possibility of hypocalcemic tetany following parenteral administration; have calcium injection readily available, particularly during first several doses of parenteral calcitonin.

    Laboratory Monitoring

    Coarse granular casts and casts containing renal tubular epithelial cells reported in some young adult volunteers at bedrest who received parenteral calcitonin in a study of its effect on immobilization osteoporosis. Clcr not altered and proteinuria not reported; urine sediment returned to normal within 4 days following drug discontinuance. Effect not reported by other investigators.

    Periodic examinations of urine sediment are recommended in patients receiving long-term parenteral therapy.

    Radiographic Monitoring

    In patients with Paget disease, carefully evaluate radiographic evidence of marked progression of pagetic lesions to rule out osteogenic sarcoma (since frequency is increased in patients with Paget disease).

    Nasal Examinations

    Periodic nasal examinations with visualization of nasal mucosa, turbinates, septum, and mucosal blood vessel status are recommended for patients receiving calcitonin nasal spray.

    Discontinue nasal spray if severe ulceration of nasal mucosa (i.e., ulcers >1.5 mm in diameter or penetrating below the mucosa, ulcers associated with heavy bleeding) occurs. For smaller ulcers, interrupt therapy until healing occurs.

    Specific Populations

    Pregnancy

    Category C.

    Lactation

    Inhibits lactation in animals. Not known whether calcitonin is distributed into human milk. Use not recommended.

    Pediatric Use

    Experience with calcitonin in children with juvenile Paget disease is very limited; the relationship between this disorder and adult Paget disease is not established.

    Experience with calcitonin in children with idiopathic juvenile osteoporosis is very limited; the relationship between this disorder and postmenopausal osteoporosis is not established.

    Data are inadequate to support use of calcitonin in children.

    Geriatric Use

    Adverse nasal effects (i.e., rhinitis, irritation, congestion) reported more frequently in patients >65 years of age receiving calcitonin nasal spray. Nasal effects described as mild.

    Common Adverse Effects

    With parenteral therapy, nausea, vomiting, injection site reaction, flushing of the face, ears, hands, and feet.

    With intranasal therapy, rhinitis, nasal symptoms, back pain.

    What other drugs will affect Calcitonin

    Bisphosphonates

    Possible reduced antiresorptive response to calcitonin in patients with Paget disease previously treated with bisphosphonates.

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords

    AI Assitant